NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02474290,Sorafenib for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3-ITD Positive AML,https://clinicaltrials.gov/study/NCT02474290,,COMPLETED,The purpose of this study is to evaluate the efficacy of sorafenib for prophylaxis of leukemia relapse in allogeneic stem cell transplant (Allo-HSCT) recipients with FLT3-ITD positive acute myeloid leukemia (AML).,NO,Acute Myeloid Leukemia|Hematopoietic Stem Cell Transplantation,DRUG: Sorafenib,"Incidence of leukemia relapse, 1 year","Overall survival, 3 year|leukemia-free survival, 3 year|Incidence of side effect of sorafenib, 6 months",,"Nanfang Hospital, Southern Medical University","Peking University People's Hospital|Third Affiliated Hospital, Sun Yat-Sen University|Zhujiang Hospital|Xiangya Hospital of Central South University|First People's Hospital of Chenzhou|The First Affiliated Hospital of Guangzhou Medical University",ALL,ADULT,PHASE2|PHASE3,202,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,Sorafenib-Flt3 AML-2015,2015-06-20,2018-07-21,2019-08-10,2015-06-17,,2019-08-26,"Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, China",
